Friday, 27 December 2024
  
Login

Australia's most trusted
source of pharma news

Friday, 27 December 2024
News

Six drugs join TGA's review list

Posted 11 December 2024 AM

Six drugs have jumped onto the TGA's review list, hinting at what could hit the Australian market by the end of next year.

These drug applications were accepted by the regulator between October and November and includes KalVista's Ekterly which will mark the first, oral on-demand treatment for hereditary angioedema (HAE) for adults and adolescents aged 12 years and older, if approved.

To see the whole article, please login

Popular

Who got booted to the May meet?
Company tops Rotten Tomato list
Best company Christmas gift is...
First out the door in '25?
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home